Bon Natural Life Ltd.

As of October 5, 2023, Bon Natural Life Ltd. is considered an attractive investment due to its undervalued status reflected in a P/E ratio of 15.2, a P/B ratio of 1.8, and an EV/EBITDA ratio of 10.5, all of which are lower than its peers, while also outperforming the Sensex.

As of October 1, 2023, there is insufficient technical data for Bon Natural Life Ltd. to assess its current stance.

Bon Natural Life Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $204 million and a net profit of $18 million. It has a market cap of $10.41 million and key metrics include a P/E ratio of 12.00 and a debt-to-equity ratio of 0.15.

As of Jun 18, Bon Natural Life Ltd. has a market capitalization of 10.41 million, with net sales of 569.90 million and a net profit of 26.20 million over the last four quarters. The company has shareholder's funds of 43.91 million and total assets of 61.77 million as of Sep 24.